Considerations for CTO Stenting
Characteristics for Stenting a CTO LesionHear his perspective
Boston Scientific is committed to providing updated medical information on its products, to healthcare professionals, which is in compliance with Indian regulations. All product related information made available on this website are for the reference of licensed healthcare professionals only. All consumers or patients are advised to consult their doctor or physician for advice on medical devices or any health related matters. Consumers or patients who use this website and rely on any information herein do so at their own risk. In no case shall Boston Scientific India Private Limited, or any of its affiliates, directors or employees be liable to any person or entity for any damages or losses resulting either directly or indirectly from the access of information provided in this website.
By clicking “Accept” you confirm your understanding and acceptance of the statements of this disclaimer.
The SYNERGY Stent is indicated for treatment of patients presenting with coronary artery total occlusion lesions and has a labeled overexpansion of up to 5.75mm allowing the physician to customize the stent to the appropriate vessel size.
SYNERGY Stent System DFU
The SYNERGY Stent’s customized architecture offers exceptional strength and conformability.
Radial Strength: Amount of radial force required to reduce the diameter of a deployed stent by 15%
Conformability: The amount of torque required to bend the stent to a specific curvature
The SYNERGY Stent’s bioabsorbable polymer and abluminal coating are designed for early healing as the polymer is gone when no longer needed, shortly after completion of drug elution at 3 months.
Results from case studies are not necessarily predictive of results in other cases. Results in other cases may vary.
Boston Scientific is committed to supporting studies evaluating the SYNERGY Stent in patient populations that interventional Cardiologists see in their everyday practice, including CTO stenting.